Table 1.
Characteristics of 21 Chinese patients with non-small cell lung cancer (NSCLC) treated with gefitinib as first-line and erlotinib as salvage therapy
| Characteristic | n | % |
|---|---|---|
| Age, years | ||
| Mean ± SD | 67.9 ± 8.1 | |
| Range | 50–83 | |
| Sex | ||
| Female | 19 | 90.5 |
| Male | 2 | 9.5 |
| Smoking history | ||
| Never smoker | 20 | 95.2 |
| Ex-light smoker | 1 | 4.8 |
| Cell type | ||
| Adenocarcinoma | 19 | 90.4 |
| Large cell carcinoma | 1 | 4.8 |
| NSCLC | 1 | 4.8 |
| EGFR mutation | ||
| Not done | 17 | 80.9 |
| Positive | 3 | 14.3 |
| Negative | 1 | 4.8 |
| Stage | ||
| IIIb | 8 | 38.1 |
| IV | 13 | 61.9 |
| ECOG performance status | ||
| 0 | 6 | 28.6 |
| 1 | 13 | 61.9 |
| 2 | 2 | 9.5 |
| Chemotherapy between two EGFR-TKIs | ||
| Yes | 8 | 38.1 |
| No | 13 | 61.9 |
EGFR epidermal growth factor receptor, ECOG Eastern Cooperative Oncology Group, TKI tyrosine kinase inhibitor